Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of SEP-363856 in schizophrenia
2019-000696-16Phase 3Completed
- Sponsor
- Sunovion
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ulotaront in schizophrenia, sponsored by Sunovion. Primary endpoint: Incidence of overall adverse events, serious adverse events, and adverse events leading to discontinuation. Started Jun 2019; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2019-000696-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000696-16.